Arsanis Inc (ASNS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Arsanis Inc (ASNS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8199
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Arsanis Inc (Arsanis) is a clinical-stage biopharmaceutical company that focuses on the development of monoclonal antibody immunotherapies for the treatment of critical infectious diseases. The company’s pipeline product portfolio includes ASN100, for staphylococcus aureus; ASN500, targets respiratory syncytial virus (RSV); ASN300, for klebsiella pneumonia; and ASN200, for escherichia coli. Arsanis works in collaboration with industry, academic and clinical research groups for antibody discovery and development. The company is funded by SV Life Sciences, OrbiMed, NeoMed, Polaris Ventures, and EMBL Ventures among others. It has operational presence in the US and Austria. Arsanis is headquartered in Waltham, Massachusetts, the US.

Arsanis Inc (ASNS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arsanis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Arsanis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arsanis Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Arsanis Raises USD45.5 Million in Series D Financing 11
Arsanis Raises USD15 million in Venture Financing 13
Arsanis Raises USD4 Million Financing 14
Arsanis Raises US$20 Million In Series B Financing 15
Licensing Agreements 17
BB200 Enters into Licensing Agreement with Arsanis 17
BB100 Enters into Licensing Agreement with Arsanis 18
Arsanis Enters into Licensing Agreement with Adimab 19
Equity Offering 20
Arsanis Raises USD46 Million in IPO of Shares 20
Arsanis Raises USD20 Million in Private Placement of Shares 22
Arsanis Raises USD5 Million in Private Placement of Preferred Stock 23
Arsanis Raises USD7 Million in Private Placement of Preferred Stock 24
Debt Offering 25
Arsanis Raises USD4.9 Million in Private Placement of Notes Due 2017 25
Arsanis Raises USD5.5 Million in Private Placement of Notes Due 2017 26
Arsanis Raises USD4 Million in Private Placement of Notes Due 2016 27
Arsanis Inc – Key Competitors 28
Arsanis Inc – Key Employees 29
Arsanis Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 13, 2018: Arsanis Reports Financial Results for Second Quarter 2018 31
May 10, 2018: Arsanis Reports Business Highlights and Financial Results for First Quarter 2018 33
Mar 09, 2018: Arsanis Reports Financial Results and Highlights for Fourth Quarter and Full Year 2017 35
Corporate Communications 37
Oct 04, 2017: Arsanis Announces Appointments of Chip Clark and David McGirr to Board of Directors and Promotion of Michael Gray to Chief Operating Officer and Chief Financial Officer 37
Product News 38
04/17/2018: Arsanis to Present Abstract On ASN500 At The 28th European Congress of Clinical Microbiology And Infectious Diseases 38
04/17/2018: Arsanis to Present Poster On ASN100 At The 28th European Congress of Clinical Microbiology And Infectious Diseases 39
Clinical Trials 40
Oct 09, 2017: Arsanis Presents Phase 1 and Preclinical Pharmacokinetic Data on Lead Product Candidate, ASN100, at IDWeek 2017 40
Sep 08, 2017: Arsanis Presents Preclinical Data on Lead Product Candidate, ASN100, at the “2017 ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance” 41
Apr 20, 2017: Arsanis Announces Initial Clinical Data for ASN100 to be Presented at the 27th European Congress of Clinical Microbiology and Infectious Disease 42
Jan 24, 2017: Arsanis Announces First Patient Dosed in Global Phase 2 Study of ASN100 for Prevention of Staphylococcus Aureus Pneumonia 43
Appendix 44
Methodology 44
About GlobalData 44
Contact Us 44
Disclaimer 44

List of Tables
Arsanis Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arsanis Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arsanis Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Arsanis Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Arsanis Raises USD45.5 Million in Series D Financing 11
Arsanis Raises USD15 million in Venture Financing 13
Arsanis Raises USD4 Million Financing 14
Arsanis Raises US$20 Million In Series B Financing 15
BB200 Enters into Licensing Agreement with Arsanis 17
BB100 Enters into Licensing Agreement with Arsanis 18
Arsanis Enters into Licensing Agreement with Adimab 19
Arsanis Raises USD46 Million in IPO of Shares 20
Arsanis Raises USD20 Million in Private Placement of Shares 22
Arsanis Raises USD5 Million in Private Placement of Preferred Stock 23
Arsanis Raises USD7 Million in Private Placement of Preferred Stock 24
Arsanis Raises USD4.9 Million in Private Placement of Notes Due 2017 25
Arsanis Raises USD5.5 Million in Private Placement of Notes Due 2017 26
Arsanis Raises USD4 Million in Private Placement of Notes Due 2016 27
Arsanis Inc, Key Competitors 28
Arsanis Inc, Key Employees 29
Arsanis Inc, Subsidiaries 30

List of Figures
Arsanis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Arsanis Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Arsanis Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Arsanis Inc (ASNS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SM Energy Co Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    SM Energy Co Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary SM Energy Co (SM Energy) is an independent upstream oil and gas company. It carries out the acquisition, exploration, development, and production of crude oil, natural gas and natural gas liquids (NGLs) …
  • Polskie Sieci Elektroenergetyczne SA:企業の戦略的SWOT分析
    Polskie Sieci Elektroenergetyczne SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Exorka GmbH:企業の戦略的SWOT分析
    Exorka GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Future Retail Limited (FRL):企業の財務・戦略的SWOT分析
    Future Retail Limited (FRL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Sanford Burnham Prebys Medical Discovery Institute-製薬・医療分野:企業M&A・提携分析
    Summary Sanford Burnham Prebys Medical Discovery Institute (Sanford Burnham) is a non-profit public benefit institute that offers medical research services. The institute offers research programs in the field of tumor initiation and maintenance, cancer metabolism and signaling networks, tumor microe …
  • Robert Half International Inc. (RHI):企業の財務・戦略的SWOT分析
    Robert Half International Inc. (RHI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Sichuan Chuantou Energy Company Ltd (600674):電力:M&Aディール及び事業提携情報
    Summary Sichuan Chuantou Energy Company Ltd (Sichuan Investment Energy), a subsidiary of Sichuan Investment Group Co Ltd is an investment holding company. The company’s business activities include operation of hydropower stations, thermal power plant and power generation plants. It develops, constru …
  • Diversicare Healthcare Services Inc (DVCR):企業の財務・戦略的SWOT分析
    Summary Diversicare Healthcare Services Inc (Diversicare), formerly Advocat Inc is a healthcare service provider that offers post acute care services and short term rehabilitation and long-term care services to nursing home patients. The company’s services include life steps rehabilitation program, …
  • Symrise AG (SY1):企業の財務・戦略的SWOT分析
    Symrise AG (SY1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Revance Therapeutics Inc (RVNC):製薬・医療:M&Aディール及び事業提携情報
    Summary Revance Therapeutics Inc (Revance Therapeutics) develops, manufactures and commercializes novel botulinum toxin products. The company’s product candidate includes RT002, an injectable formulation of botulinum toxin type for the treatment of glabellar lines, cervical dystonia, and plantar fas …
  • Technical University of Denmark:製薬・医療:M&Aディール及び事業提携情報
    Summary Technical University of Denmark (DTU) is an educational and research service provider. The university offers undergraduate programs, graduate programs, PhD programs, BSc programs, MSc programs, guest student services, accommodation services and others. It conducts research programs in the ar …
  • Annexon Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Annexon Inc (Annexon) is a developer of therapeutic products and pathway inhibitors for the treatment of neurological disorders. The company develops treatments for Huntington’s disease and Alzheimer’s disease by targeting complement-mediated neurodegeneration. Its lead drug candidates inclu …
  • Endo Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Endo Pharmaceuticals Inc (Endo Pharmaceuticals), a subsidiary of Endo International plc is a healthcare products provider that offers medicinal products. The company manufactures and distributes generic pharmaceutical products and over-the-counter medications. Its products include testostero …
  • Detour Gold Corp:企業の戦略・SWOT・財務分析
    Detour Gold Corp - Strategy, SWOT and Corporate Finance Report Summary Detour Gold Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Spineology Inc-医療機器分野:企業M&A・提携分析
    Summary Spineology Inc (Spineology) is a medical device company that develops and designs spinal implants. The company offers products such as pedicular fixation system, interbody fusion system, deployable grafting system, amniotic fixation system, allografts, retractor system, liquid tissue matrix, …
  • IBC Solar AG:電力:M&Aディール及び事業提携情報
    Summary IBC Solar AG (IBC Solar), formerly IBC Solartechnik, is a solar energy company that provides photovoltaic and energy storage solutions and services. The company’s product range includes solar parks, self-consumption systems for commercial enterprises and private households, diesel hybrid sol …
  • BiosanaPharma BV:製薬・医療:M&Aディール及び事業提携情報
    Summary BiosanaPharma BV (Biosana) is a biotechnology company engaged in the development of monoclonal antibody biologicals (mAbs), biosimilars and biobetters. Its pipeline products include BP001: biosimilar of Omalizumab (anti-allergy); BP002: biosimilar of Denosumab (anti-osteoporosis); BOX001: or …
  • DBV Technologies SA (DBV):製薬・医療:M&Aディール及び事業提携情報
    Summary DBV Technologies SA (DBV) is a biopharmaceutical company that develops products for the diagnosis and treatment of food and pediatric allergies. The company develops and markets non-invasive epicutaneous delivery technology and products for healthcare markets. Its viaskin technology platform …
  • MSC Industrial Direct Co Inc (MSM):企業の財務・戦略的SWOT分析
    MSC Industrial Direct Co Inc (MSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Shin-Etsu Chemical Co Ltd (4063):企業の財務・戦略的SWOT分析
    Shin-Etsu Chemical Co Ltd (4063) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆